BanzelTreatment for Lennox-Gastaut Syndrome
Update: Banzel Now FDA Approved - November 14, 2008
Eisai Resubmits NDA for the Anti-epilepsy Drug Rufinamide
RIDGEFIELD PARK, N.J., November 18, 2005 -- Eisai Medical Research Inc. (Headquarters: Ridgefield Park, NJ, President: Mindell Seidlin), a U.S. pharmaceutical subsidiary of Eisai Co., Ltd. , announced today that they resubmitted the New Drug Application (NDA) for the anti-epilepsy agent rufinamide on Nov. 16, 2005. Eisai Medical Research had withdrawn the original NDA in early November and has supplemented its filing to include copies of some of the data from the original NDA in a more accessible electronic format.
Rufinamide has been evaluated as an adjunctive treatment for partial-onset seizures in adult and adolescent patients (12 years and older) and as adjunctive treatment for seizures associated with Lennox-Gastaut Syndrome (LGS) in children (4 years and older).
Source: Eisai Co., Ltd.
Posted: November 2005
- Eisai Receives Approval for Antiepileptic Drug Banzel (rufinamide) As Adjunctive Treatment For Pediatric Patients - February 16, 2015
- FDA Approves Banzel (rufinamide) Oral Suspension, 40 mg/mL - March 4, 2011
- FDA Approves Banzel (rufinamide) as Adjunctive Treatment for Severe Epilepsy Disorder - November 17, 2008
- Eisai Submits New Drug Application to the FDA for Anti-epileptic Drug Rufinamide - September 13, 2005